钠–葡萄糖共转运蛋白2抑制剂治疗多囊卵巢综合征研究进展

Research Progress of Sodium-Glucose Cotransporter 2 Inhibitor in the Treatment of Polycystic Ovary Syndrome

多囊卵巢综合征是无排卵性不孕最常见的原因,其发病机制主要与胰岛素抵抗、高雄激素血症以及肥胖相关。目前尚无根治多囊卵巢综合征的治疗手段,以对症治疗为主,通过减重和药物干预可以改善患者代谢及生殖结局,常用的药物有二甲双胍和避孕药。钠–葡萄糖共转运蛋白2抑制剂是一种新型降糖药物,具有减重、降糖、改善胰岛素抵抗、抗炎等作用,可使多囊卵巢综合征患者获益,相关的临床实验也逐渐增多,取得了可观的疗效,本文总结了钠–葡萄糖共转运蛋白2抑制剂的治疗多囊卵巢综合征可能的作用机制及最新进展,旨在为临床用药提供参考。

Polycystic ovary syndrome is the most common cause of anovulatory infertility, and its pathogenesis is mainly related to insulin resistance, hyperandrogenemia and obesity. At present, there is no rad-ical treatment for polycystic ovary syndrome, mainly symptomatic treatment, weight loss and drug intervention can improve patients’ metabolism and reproductive outcome, and the commonly used drugs are metformin and contraceptive. Sodium-glucose cotransporter 2 inhibitor is a new type of hypoglycemic drug, which may benefit patients with polycystic ovary syndrome by reducing weight, reducing blood glucose, improving insulin resistance and anti-inflammation, and the related clinical trials are gradually increasing. Considerable efficacy has been achieved. This paper summarizes the possible mechanism and latest progress of sodium-glucose cotransporter 2 inhibitors in the treat-ment of polycystic ovary syndrome, aiming to provide reference for clinical medication.